Year-end Sale % OFF 
Abstract
In most countries, the supply of corneal material do not meet the demands for corneal transplantation. This has been exacerbated by COVID‐19. Patients have not been seen during lockdown. Many are presenting late. There has been fewer operations done during the pandemic resulting in a backlog. Even in normal times, there are cases of corneal blindness not amenable to cadaveric corneal transplantation. The clinical and research community have two tasks. One is to develop artificial corneae or contructs through biotechnology to replace cadaveric transplantation. The other is to improve keratoprostheses which are used for vascularised corneae and multiple previous failed grafts (Boston KPro1 and similar) and for dry keratinised ocular surface (the OOKP and alternatives).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
